Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 2, 2008, Pages 738-743

  Seong, Churl Min ^a   Park, Woo Kyu ^a   Park, Chul Min ^a   Kong, Jae Yang ^a   Park, No Sang ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

5 HT6 Receptor antagonist; Alzheimer's disease; Quinoline 2,4 dione; Schizophrenia

Indexed keywords

1 BENZENESULFONYL 5 METHOXY N,N DIMETHYLTRYPTAMINE; 3 (4 HYDROXYPHENYL) 3 METHYLQUINOLINE 2,4 DIONE; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIDINYL]BENZENESULFONAMIDE; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; 5,7 DICHLORO 3 PHENYL 3 METHYLQUINOLINE 2,4 DIONE; ADENYLATE CYCLASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; QUINOLINE DERIVATIVE; SB 357134; SEROTONIN 6 ANTAGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

CELL LINE; HUMANS; QUINOLINES; RADIOLIGAND ASSAY; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 38149019214     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.045     Document Type: Article

References (27)

1. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., and Humphrey P.P. Pharmacol. Rev. 46 (1994) 157
2. Ruat M., Traiffort E., and Arrang J.M. Biochem. Biophys. Res. Commun. 193 (1993) 268
3. Kohen R., Metcalf M.A., Khan N., Druck T., Huebner K., Lachowicz J.E., Meltzer H.Y., Sibley D.R., Roth B.L., and Hamblin M.W. J. Neurochem. 66 (1996) 47
4. Gerard C., Martres M.-P., Lefevre K., Miquel M.-C., Verge D., Lanfumey L., Doucet E. ., Hamon M., and El Mestikawy S. Brain Res. 746 (1997) 207
5. Ward R.P., Hamblin M.W., Lachowicz J.E., Hoffman B.J., Sibley D.R., and Dorsa D.M. Neuroscience 64 (1995) 1105
6. Roth B.L., Craig S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., Meltzer H.Y., and Sibley D.R. J. Pharmacol. Exp. Ther. 268 (1994) 1403
7. Lindner M.D., Hodges Jr. D.B., Hogan J.B., Orie A.F., Corsa J.A., Barten D.M., Polson C., Robertson B.J., Guss V.L., Gillman K.W., Starrett Jr. J.E., and Gribkoff V.K. J. Pharmacol. Exp. Ther. 307 (2003) 682
8. Pullagurla M., Bondareva T., Young R., and Glennon R.A. Pharmacol. Biochem. Behav. 78 (2004) 263
9. Minabe Y., Shirayama Y., Hashimoto K., Routledge C., Hagan J.J., and Ashby Jr. C.R. Synapse 52 (2004) 20
10. Lacroix L.P., Dawson L.A., Hagan J.J., and Heidbreder C.A. Synapse 51 (2004) 158
11. King M.V., Sleight A.J., Woolley M.L., Topham I.A., Marsden C.A., and Fone K.C. Neuropharmacology 47 (2004) 195
12. Sleight A.J., Boess F.G., Bos M., Levet-Trafit B., Riemer C., and Bourson A. Br. J. Pharmacol. 124 (1998) 556
13. Bromidge S.M., Brown A.M., Clarke S.E., Dodgson K., Gager T., Grassam H.L., Jeffrey P.M., Joiner G.F., King F.D., Middlemiss D.N., Moss S.F., Newman H., Riley G., Routledge C., and Wyman P. J. Med. Chem. 42 (1999) 202
14. Bromidge S.M., Clarke S.E., Gager T., Griffith K., Jeffrey P., Jennings A.J., Joiner G.F., King F.D., Lovell P.J., Moss S.F., Newman H., Riley G., Rogers D., Routledge C., Serafinowska H., and Smith D.R. Bioorg. Med. Chem. Lett. 11 (2001) 55
15. Tsai Y., Dukat M., Slassi A., MacLean N., Demchyshyn L., Savage J.E., Roth B.L., Hufesein S., Lee M., and Glennon R.A. Bioorg. Med. Chem. Lett. 10 (2000) 2295
16. Russell M.G., Baker R.J., Barden L., Beer M.S., Bristow L., Broughton H.B., Knowles M., McAllister G., Patel S., and Castro J.L. J. Med. Chem. 44 (2001) 3881
17. Riemer C., Borroni E., Levet-Traft B., Martin J.R., Poli S., Porter R.H., and Bos M. J. Med. Chem. 46 (2003) 1273
18. Slassi A., Isaac M., and O'Brien A. Expert Opin. Ther. Pat. 12 (2002) 513
19. Jnaneshwara G.K., Bedekar A.V., and Deshpande V.H. Syn. Comm. 29 (1999) 3627
20. Drummond A.H., Bucher F., and Levitan I.B. Brain Res. 184 (1980) 163
21. Drummond A.H., Bucher F., and Levitan I.B. J. Biol. Chem. 255 (1980) 6679
22. i) values.
23. Hyun M.H., and Min C.S. Chirality 10 (1998) 592
24. Tambute A., Siret L., Caude M., Begos A., and Rosset R. Chirality 3 (1991) 427
25. 2 349.0272, found 349.0278; Crystallographic data (excluding structure factors) for the structure in this paper have been deposited with Cambridge Crystallographic Data Center as supplementary publication numbers CCDC 650024. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (0)1223-336033 or e-mail: deposit@ccdc.com.ac.uk].
26. Routledge C., Bromidge S.M., Moss S.F., Price G.W., Hirst W., Newman H., Riley G., Gager T., Stean T., Upton N., Clarke S.E., Brown A.M., and Middlemiss D.N. Br. J. Pharmacol. 130 (2000) 1606
27. 2, and 100 μM 1-methyl-3-isobutylxanthine(IBMX). Incubation was started by addition of membrane suspension and test compounds. Following 20 min incubation at 37 °C, intracellular cAMP levels were measured by EIA (enzyme-immunoassay), and a compound showing inhibitory effects on 5-HT-stimulated cAMP accumulation was classified as an antagonist.